OBJECTIVE: To probe into the economics of Tongluo Kaibi tablets

Biqi capsules and Gulong capsules combined with methotrexate in the treatment of rheumatoid arthritis

so as to provide reference for clinical drug selection and decision-making by health and medical insurance departments. METHODS: Based on the health system perspective

a three-month decision tree model was constructed by using Treeage Pro software

and cost-effectiveness analysis of three kinds of traditional Chinese patent medicines combined with methotrexate in the treatment of rheumatoid arthritis was performed. Efficacy data and adverse drug reactions data were derived from published randomized controlled trials. The incremental cost-effectiveness ratio（ ICER） was used as the evaluation index and sensitivity analysis was carried out. RESULTS: Tongluo Kaibi tablets combined with methotrexate had the lowest treatment cost and the best effect

ICER<0. The results of sensitivity analysis showed that the most influential factors on the results were the total effective rate and the drug price of Tongluo Kaibi tablets. When willing to pay（ WTP） was from 0 and 2 000 yuan

the acceptable probability of patients in the Tongluo Kaibi tablets group was higher than that in the Gulong capsules group; when WTP was > 18 yuan

the acceptable probability of patients in theTongluo Kaibi tablets group was higher than that in the Biqi capsules group. CONCLUSIONS: Among the regimens of Tongluo Kaibi tablets

Biqi capsules and Gulong capsules combined with methotrexate in the treatment of rheumatoid arthritis

Tongluo Kaibi tablets combined with methotrexate has the most cost-effectiveness advantage

followed by Biqi capsules

and Gulong capsules has the least economy.